Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | June 04, 2026 | June 08, 2026 |
| Penumbra IncPEN · Entity 3430 | President | April 15, 2020 | April 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 65,278 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 8,829 · Balance 65,278 F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,000 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,000 F2: These shares are held by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.
F2: These shares are held by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee.
Penumbra Inc
Report date April 15, 2020 · Filed April 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,351 |
Last balance in matching sequence
After 2020-04-15 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 1 · 2020-04-15 · Sale · Disposed 200 · Balance 157,651 F1: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2: This transaction was executed in multiple trades at prices ranging from $164.78 to $165.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F3: Shares are held by the Kosaraju Family Trust. Row 2 · 2020-04-15 · Sale · Disposed 100 · Balance 157,551 F1: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3: Shares are held by the Kosaraju Family Trust. Row 3 · 2020-04-15 · Sale · Disposed 300 · Balance 157,251 F1: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4: This transaction was executed in multiple trades at prices ranging from $167.16 to $167.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F3: Shares are held by the Kosaraju Family Trust. Row 4 · 2020-04-15 · Sale · Disposed 217 · Balance 157,034 F1: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5: This transaction was executed in multiple trades at prices ranging from $168.01 to $168.64. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F3: Shares are held by the Kosaraju Family Trust. Row 5 · 2020-04-15 · Sale · Disposed 600 · Balance 156,434 F1: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6: This transaction was executed in multiple trades at prices ranging from $169.04 to $169.69. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F3: Shares are held by the Kosaraju Family Trust. Row 6 · 2020-04-15 · Sale · Disposed 383 · Balance 156,051 F1: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7: This transaction was executed in multiple trades at prices ranging from $170.05 to $170.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F3: Shares are held by the Kosaraju Family Trust. Row 7 · 2020-04-15 · Sale · Disposed 700 · Balance 155,351 F1: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8: This transaction was executed in multiple trades at prices ranging from $171.22 to $171.65. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F3: Shares are held by the Kosaraju Family Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2: This transaction was executed in multiple trades at prices ranging from $164.78 to $165.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3: Shares are held by the Kosaraju Family Trust.
F4: This transaction was executed in multiple trades at prices ranging from $167.16 to $167.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $168.01 to $168.64. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $169.04 to $169.69. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $170.05 to $170.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $171.22 to $171.65. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 46,575 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 23:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000191 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,278 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 15,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000167 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,449 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 16:30 UTC | NEVRO CORP NVRO · Entity 12422 | Disposition to issuerCommon Stock | 46,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050475 · ownership.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 16:51 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001444380-25-000004 · wk-form4_1735854709.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,575 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 19,169 restricted stock units. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 16:57 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 2,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000499 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,342 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 19,169 restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 16:10 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000382 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,525 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 19,988 restricted stock units. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000329 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,092 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 18:58 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 19,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000266 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,655 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 23, 2024 or (ii) the next Annual Meeting following May 23, 2024, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 19,988 RSUs. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 19:05 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000203 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,486 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 7,573 restricted stock units. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 16:51 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 731 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000005 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,396 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 7,573 restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 17:00 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 819 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000305 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,665 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 7,573 restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:09 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 619 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000198 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,846 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 8,393 restricted stock units. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:38 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 4,661 | $0.00 Strike: $57.62 | $0.00 |
DisclosureSEC source: 0001610717-23-000172 · form4.xml · derivative · entry 3 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,661 Underlying: Class A Common Stock · 4,661 shares Expires 2033-06-14 F3 · derivative.exercise_date: 1/12th of the total number of shares subject to the option vest on each monthly anniversary measured from June 14, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:38 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 1,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000172 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,443 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 17:17 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 6,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000076 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,227 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2023 or (ii) the next Annual Meeting following May 25, 2023, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 8,393 RSUs. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 16:41 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-016269 · form4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,473 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 5,794 restricted stock units. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 16:37 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 397 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000253 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,038 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 5,794 restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 17:50 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 337 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018222 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,641 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 5,794 restricted stock units. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-22-017560 · doc1.xml · derivative · entry 3 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,167 Underlying: Class A Common Stock · 10,000 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, originally for 130,000 shares, of which 45,833 have been exercised, vested as to one forty-eighth of the shares on April 29, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $11.48 | $114,800.00 |
DisclosureSEC source: 0001567619-22-017560 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013691 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,304 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,614 restricted stock units. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $39.62 | $0.00 |
DisclosureSEC source: 0001567619-22-013118 · doc1.xml · derivative · entry 3 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Class A Common Stock · 5,300 shares Expires 2032-06-15 F3 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 15, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013118 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,578 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:02 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011890 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,973 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 26, 2022 or (ii) the next Annual Meeting following May 26, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 6,614 restricted stock units. Read SEC document |
| May 16, 2022 Filed May 17, 2022 21:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-22-011125 · doc1.xml · derivative · entry 3 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,167 Underlying: Class A Common Stock · 15,000 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, originally for 130,000 shares, of which 35,833 have been exercised, vested as to one forty-eighth of the shares on April 29, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. Read SEC document |
| May 16, 2022 Filed May 17, 2022 21:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 15,000 | $11.48 | $172,200.00 |
DisclosureSEC source: 0001567619-22-011125 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:48 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 190 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008043 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,818 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 2,459 restricted stock units. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 18:03 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 169 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000345 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,628 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 2,459 restricted stock units. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 23:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $150.38 | $225,568.95 |
DisclosureSEC source: 0001567619-22-000372 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,000 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 23:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $150.06 | $225,084.45 |
DisclosureSEC source: 0001567619-21-021235 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,500 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $168.68 | $50,604.00 |
DisclosureSEC source: 0001567619-21-018801 · doc1.xml · nonDerivative · entry 5 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,000 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F5 · price: This transaction was executed in multiple trades at prices ranging from $168.49 to $168.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $167.63 | $16,763.00 |
DisclosureSEC source: 0001567619-21-018801 · doc1.xml · nonDerivative · entry 4 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,300 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F2 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $166.60 | $66,641.32 |
DisclosureSEC source: 0001567619-21-018801 · doc1.xml · nonDerivative · entry 3 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,400 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $166.23 to $167.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $165.14 | $99,084.42 |
DisclosureSEC source: 0001567619-21-018801 · doc1.xml · nonDerivative · entry 2 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,800 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F3 · price: This transaction was executed in multiple trades at prices ranging from $164.57 to $165.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $163.85 | $16,385.00 |
DisclosureSEC source: 0001567619-21-018801 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,400 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F2 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 22:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $159.52 | $175,476.95 |
DisclosureSEC source: 0001209191-21-057709 · doc4.xml · nonDerivative · entry 2 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $158.94 to $159.81. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 22:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $157.71 | $63,085.04 |
DisclosureSEC source: 0001209191-21-057709 · doc4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $157.20 to $157.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 18:34 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 2,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-016695 · doc1.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,459 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on August 31 of each year, beginning August 31, 2022, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 2,459 RSUs. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $164.05 | $16,405.00 |
DisclosureSEC source: 0001209191-21-053394 · doc4.xml · nonDerivative · entry 5 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $163.25 | $97,948.50 |
DisclosureSEC source: 0001209191-21-053394 · doc4.xml · nonDerivative · entry 4 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,100 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F5 · price: This transaction was executed in multiple trades at prices ranging from $162.90 to $163.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $162.27 | $81,135.00 |
DisclosureSEC source: 0001209191-21-053394 · doc4.xml · nonDerivative · entry 3 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $161.66 to $162.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $160.56 | $16,056.00 |
DisclosureSEC source: 0001209191-21-053394 · doc4.xml · nonDerivative · entry 2 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $157.72 | $31,543.00 |
DisclosureSEC source: 0001209191-21-053394 · doc4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,300 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $157.32 to $158.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 241 | $185.96 | $44,815.18 |
DisclosureSEC source: 0001209191-21-048195 · doc4.xml · nonDerivative · entry 4 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F6 · price: This transaction was executed in multiple trades at prices ranging from $185.39 to $186.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $184.43 | $73,770.92 |
DisclosureSEC source: 0001209191-21-048195 · doc4.xml · nonDerivative · entry 3 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,741 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F5 · price: This transaction was executed in multiple trades at prices ranging from $184.07 to $184.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $183.07 | $73,229.92 |
DisclosureSEC source: 0001209191-21-048195 · doc4.xml · nonDerivative · entry 2 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,141 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $182.89 to $183.525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 459 | $182.32 | $83,684.33 |
DisclosureSEC source: 0001209191-21-048195 · doc4.xml · nonDerivative · entry 1 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,541 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $181.69 to $182.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $201.74 | $80,695.08 |
DisclosureSEC source: 0001209191-21-043307 · doc4.xml · nonDerivative · entry 4 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F6 · price: This transaction was executed in multiple trades at prices ranging from $201.32 to $201.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $200.03 | $100,016.10 |
DisclosureSEC source: 0001209191-21-043307 · doc4.xml · nonDerivative · entry 3 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,400 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F5 · price: This transaction was executed in multiple trades at prices ranging from $199.88 to $200.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $199.40 | $79,760.00 |
DisclosureSEC source: 0001209191-21-043307 · doc4.xml · nonDerivative · entry 2 Kosaraju Sridhar · CIK 0001651325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,900 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $198.84 to $199.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: These shares are held by the Kosaraju Family Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.